JP2020507569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507569A5 JP2020507569A5 JP2019542717A JP2019542717A JP2020507569A5 JP 2020507569 A5 JP2020507569 A5 JP 2020507569A5 JP 2019542717 A JP2019542717 A JP 2019542717A JP 2019542717 A JP2019542717 A JP 2019542717A JP 2020507569 A5 JP2020507569 A5 JP 2020507569A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- use according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457219P | 2017-02-10 | 2017-02-10 | |
| US62/457,219 | 2017-02-10 | ||
| PCT/IB2018/050783 WO2018146612A1 (en) | 2017-02-10 | 2018-02-08 | 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507569A JP2020507569A (ja) | 2020-03-12 |
| JP2020507569A5 true JP2020507569A5 (enExample) | 2021-03-18 |
| JP7161481B2 JP7161481B2 (ja) | 2022-10-26 |
Family
ID=61274309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542717A Expired - Fee Related JP7161481B2 (ja) | 2017-02-10 | 2018-02-08 | １－（４－アミノ－５－ブロモ－６－（１ｈ－ピラゾール－１－イル）ピリミジン－２－イル）－１ｈ－ピラゾール－４－オール及びがんの治療におけるその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11078191B2 (enExample) |
| EP (1) | EP3579874B1 (enExample) |
| JP (1) | JP7161481B2 (enExample) |
| KR (1) | KR20190115053A (enExample) |
| CN (1) | CN110290808B (enExample) |
| AU (2) | AU2018217963B2 (enExample) |
| CA (1) | CA3051986A1 (enExample) |
| DK (1) | DK3579874T3 (enExample) |
| ES (1) | ES2893006T3 (enExample) |
| HU (1) | HUE057337T2 (enExample) |
| IL (1) | IL268549B (enExample) |
| PL (1) | PL3579874T3 (enExample) |
| PT (1) | PT3579874T (enExample) |
| SI (1) | SI3579874T1 (enExample) |
| WO (1) | WO2018146612A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108495651A (zh) * | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| US10933064B2 (en) * | 2017-05-31 | 2021-03-02 | Novartis Ag | Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and new salts |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| AU2014276440A1 (en) * | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017025918A1 (en) * | 2015-08-11 | 2017-02-16 | Novartis Ag | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
-
2018
- 2018-02-08 CN CN201880011779.3A patent/CN110290808B/zh not_active Expired - Fee Related
- 2018-02-08 AU AU2018217963A patent/AU2018217963B2/en not_active Ceased
- 2018-02-08 US US16/484,183 patent/US11078191B2/en not_active Expired - Fee Related
- 2018-02-08 KR KR1020197025984A patent/KR20190115053A/ko not_active Abandoned
- 2018-02-08 PT PT18707151T patent/PT3579874T/pt unknown
- 2018-02-08 EP EP18707151.9A patent/EP3579874B1/en active Active
- 2018-02-08 WO PCT/IB2018/050783 patent/WO2018146612A1/en not_active Ceased
- 2018-02-08 SI SI201830420T patent/SI3579874T1/sl unknown
- 2018-02-08 PL PL18707151T patent/PL3579874T3/pl unknown
- 2018-02-08 HU HUE18707151A patent/HUE057337T2/hu unknown
- 2018-02-08 CA CA3051986A patent/CA3051986A1/en active Pending
- 2018-02-08 DK DK18707151.9T patent/DK3579874T3/da active
- 2018-02-08 JP JP2019542717A patent/JP7161481B2/ja not_active Expired - Fee Related
- 2018-02-08 ES ES18707151T patent/ES2893006T3/es active Active
-
2019
- 2019-08-06 IL IL268549A patent/IL268549B/en unknown
-
2020
- 2020-10-19 AU AU2020256467A patent/AU2020256467B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213684A1 (en) | Combination therapies comprising antibody molecules to tim-3 | |
| JP7695819B2 (ja) | Ｐｄ－ｌ１に対する抗体分子およびその使用 | |
| US20260021178A1 (en) | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor | |
| JP7770760B2 (ja) | ヒトｒｏｒ１に対する抗体を含む抗体－薬物コンジュゲートおよびその使用 | |
| EP3411398B1 (en) | Targeted therapeutic agents and uses thereof | |
| CN107148285B (zh) | 吡咯并苯并二氮杂䓬-抗体缀合物 | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| WO2020130125A1 (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| JP2021523122A5 (enExample) | ||
| JP2019503349A5 (enExample) | ||
| JP2020527572A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2020500834A5 (enExample) | ||
| JP2023515675A5 (enExample) | ||
| TW202216207A (zh) | 抗體-藥物結合物及cdk9抑制劑之組合 | |
| JP2023510199A5 (enExample) | ||
| TW201836610A (zh) | Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案 | |
| JP2020505350A5 (enExample) | ||
| JP2020523414A (ja) | Ｌｇｒ５に結合する抗体薬物複合体 | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2021501800A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 |